De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, with a price target of $22.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors tied to Unicycive’s lead asset, oxylanthanum carbonate (OLC), and the company’s strategic positioning. The FDA’s acceptance of the resubmitted NDA under a standard Class II review, with issues previously confined to third‐party manufacturing rather than clinical data, substantially reduces regulatory risk in his view. He highlights management’s increased emphasis on commercial planning versus the prior submission cycle, interpreting this as a sign of confidence in approval and execution. In addition, he underscores the potential for Unicycive to become an attractive acquisition candidate, given OLC’s differentiated profile and the de-risked regulatory pathway.

Ramakanth also bases his rating on the sizeable commercial opportunity and structured launch plan. His projections assume a 3Q26 launch following the late‑2Q26 PDUFA date, with initial, risk-adjusted revenues building into a more meaningful ramp in 2027, supported by the expectation of TDAPA status and premium pricing. He points to the roughly 450,000-patient U.S. market and argues that even modest share capture could lead to substantial long-term revenue. In parallel, he views management’s steps toward commercial readiness—selective hiring, contingent sales force arrangements, early engagement with major dialysis organizations, and the planned patient hub to drive uptake among a concentrated prescriber base—as key elements that should support adoption and further justify the Buy rating and $22 price target.